Monitor U.S. patent issuance and Track One examination progress for near-term clarity on IP scope. The patent updates support partnering discussions but do not change near-term clinical or financial outlook.
Price Chart
Executive Summary
Oncolytics Biotech filed an 8-K announcing updates to its intellectual property portfolio for pelareorep. A new method-of-use patent covering pelareorep as an immunotherapy for cancer has been issued in several countries, with U.S. issuance expected soon. The company also plans to file a Track One prioritized patent application and is working on a next-generation pelareorep composition-of-matter patent, aiming to extend protection into the late 2040s. This is a routine IP portfolio update with no financial data or near-term revenue impact.
Key Facts
- New method-of-use patent covering pelareorep as an immunotherapy for cancer issued in several countries; U.S. issuance expected in the near term.
- Three patent application families pending, including two method-of-use patents; one expected to be converted to a Track One prioritized U.S. application this quarter.
- Company expects to add a new composition-of-matter patent covering a modified next-generation pelareorep, with potential for up to 20 years of protection from filing date.
- Existing manufacturing patent protection runs through 2044; new patents intended to extend protection into the late 2040s.
- No financial figures, revenue, earnings, or deal values disclosed in the filing.
Financial Impact
No financial impact disclosed; patent portfolio extension is a long-term strategic move with no immediate revenue or cost effect.
Risk Factors
- Patent issuance and scope are subject to USPTO review; Track One prioritized examination does not guarantee allowance.
- Next-generation pelareorep composition-of-matter patent requires further studies and academic collaboration; timeline uncertain.
- No clinical data or regulatory milestones announced; stock may not react to IP portfolio updates alone.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001129928-26-000070 |
| Document: oncyipportfolioupdate.htm | 0001129928-26-000070 |
| Document: 0001129928-26-000070-index-headers.html | 0001129928-26-000070 |
| Document: 0001129928-26-000070-index.html | 0001129928-26-000070 |
| Document: 0001129928-26-000070.txt | 0001129928-26-000070 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | 8-K | $0.4986 | awaiting T+20 | — | $0.4700 (−5.74%) |
Oct 20, 2026 6d ago | Press Release | $0.4986 | awaiting T+20 | — | $0.4700 (−5.74%) |
Oct 14, 2026 12d ago | 8-K | $0.5382 | awaiting T+20 | — | $0.4700 (−12.67%) |
Oct 13, 2026 13d ago | 8-K | $0.4900 | awaiting T+20 | — | $0.4700 (−4.08%) |
Oct 6, 2026 20d ago | DEFA14A | $0.6000 | awaiting T+20 | — | $0.4700 (−21.67%) |
Oct 6, 2026 20d ago | DEF 14A | $0.6000 | awaiting T+20 | — | $0.4700 (−21.67%) |
Sep 29, 2026 27d ago | 8-K | $0.6745 | awaiting T+20 | — | $0.4700 (−30.32%) |
Sep 28, 2026 28d ago | 8-K | $0.6630 $0.4732 | ▼ −28.63% | ▼ −28.60% | $0.4700 (−29.11%) |
Sep 10, 2026 6w ago | 8-K | $0.7720 $0.5444 | ▼ −29.48% | ▼ −31.61% | $0.4700 (−39.12%) |
Jul 20, 2026 14w ago | 8-K | $0.8500 $0.8227 | ▼ −3.21% | ▼ −7.33% | $0.4700 (−44.71%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers